CDTX — Cidara Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapNeutral

Annual income statement for Cidara Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	12.1	49.6	64.4	23.3	1.27
Cost of Revenue
Gross Profit	—	—	64.4	—	—
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	83.9	91.8	98	50.3	177
Operating Profit	-71.8	-42.3	-33.5	-27.1	-176
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	-72.1	-42.5	-33.3	-25.1	-170
Provision for Income Taxes
Net Income After Taxes	-72.1	-42.5	-33.6	-25.1	-170
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-72.1	-42.5	-33.6	-22.9	-170
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-74.9	-42.5	-33.6	-22.9	-170
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-36	-16.2	-9.61	-5.74	-13.5